Molecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides

Dharap, S.; Qiu, Bo; Williams, Gregory C.; Sinko, Patrick J.; Stein, Stanley J.; Minko, Tamara

doi:10.1016/s0168-3659(03)00209-8

Cited by 161 publications

(118 citation statements)

References 34 publications

Supporting

Mentioning

112

Contrasting

Order By: Relevance

“…LHRH peptide is a ligand for the receptors that are overexpressed in plasma membrane of breast, ovarian, and prostate cancer cells [26,29,37] and, as found in the present study, in some types of lung cancer cells. In contrast, the expression of these receptors in healthy organs in most cases is non-detectable [23,38].…”

Section: Discussionsupporting

confidence: 83%

“…Cy5.5 represents a class of very effective dyes currently used as cancer imaging agents. The systems were prepared and characterized using procedures previously developed in our laboratory [7,[23][24][25][26][27][28]. Based on the results of dynamic light scattering and atomic force microscope measurements, the average size of dendrimers, PEG polymers, and liposomes were about 5, 30 and 100 nm respectively.…”

Section: Nanocarriersmentioning

confidence: 99%

“…The expression of a targeted LHRH receptor was measured in mRNA isolated from cell lysates and commercially available mRNA from healthy human organs by the reverse transcription polymerase chain reaction (RT-PCR) as previously described [23,26,29]. In part of the experiments, LHRH peptide was labeled with rhodamine as previously described [24] and incubated within 48 h with lung cancer cells.…”

Section: In Vitro Experimentsmentioning

confidence: 99%

See 2 more Smart Citations

Receptor targeted polymers, dendrimers, liposomes: Which nanocarrier is the most efficient for tumor-specific treatment and imaging?

Saad

Garbuzenko

Ber

et al. 2008

Journal of Controlled Release

220

165

View full text Add to dashboard Cite

To compare the influence of different characteristics of nanocarriers on the efficacy of chemotherapy and imaging, we designed, characterized, and evaluated three widely used nanocarriers: linear polymer, dendrimer and liposome in vitro and in vivo. These nanocarriers delivered the same anticancer drug (paclitaxel) and/or imaging agent (Cy5.5). A synthetic analog of LHRH peptide targeted to receptors overexpressed on the membrane of cancer cells was attached to the nanocarriers as a tumor targeting moiety. Significant differences were found between various studied non-targeted carriers in their cellular internalization, cytotoxicity, tumor and organ distribution and anticancer efficacy. LHRH peptide substantially enhanced intratumoral accumulation and anticancer efficacy of all delivery systems and minimized their adverse side effects. For the first time, the present study revealed that the targeting of nanocarriers to tumorspecific receptors minimizes the influence of the architecture, composition, size and molecular mass of nanocarriers on the efficacy of imaging and cancer treatment.

show abstract

Section: Discussionsupporting

confidence: 83%

Section: Nanocarriersmentioning

confidence: 99%

Section: In Vitro Experimentsmentioning

confidence: 99%

See 1 more Smart Citation

Receptor targeted polymers, dendrimers, liposomes: Which nanocarrier is the most efficient for tumor-specific treatment and imaging?

Saad

Garbuzenko

Ber

et al. 2008

Journal of Controlled Release

220

165

View full text Add to dashboard Cite

show abstract

“…Overexpression of the luteinizing hormone-releasing hormone (LHRH) receptor has been reported in breast, ovarian, and prostate cancer cells, [16][17][18][19] whereas no detectable expression of LHRH receptors has been observed in most visceral organs. Previous reports by Dharap et al 17,20 and Tang et al 19 demonstrated that LHRH peptide could be used as a targeting moiety on drug-delivery systems to enhance drug uptake by breast, ovarian, and prostate cancer cells, and reduce the relative availability of the toxic drug to normal cells.…”

Section: Liu Et Almentioning

confidence: 99%

TAT-LHRH conjugated low molecular weight chitosan as a gene carrier specific for hepatocellular carcinoma cells

Liu¹,

Dong²,

Zhu³

et al. 2014

IJN

View full text Add to dashboard Cite

To develop a chitosan-based nonviral gene carrier capable of delivering genes specifically into hepatoma cells, a bifunctional peptide composed of the TAT (transactivator of transcription) peptide and luteinizing hormone-releasing hormone (LHRH) was conjugated with low molecular weight chitosan, resulting in a TAT-LHRH-chitosan conjugate (TLC). TLC/DNA nanoparticles (TLCDNPs) were characterized by agarose gel retardation, atomic force microscopy, and dynamic light scattering analysis. In vitro targeting specificity and transfection efficiency were analyzed with a GE IN Cell Analyzer 2000 High-Content Cellular Analysis System. The results demonstrated that TLC had stronger DNA condensing power than unmodified chitosan, and that TLCDNPs were of roughly round shape with average diameter of 70–85 nm and zeta potential of +30 mV and were relatively stable in solution. The in vitro study demonstrated TLC was highly selective for hepatoma cells and essentially nontoxic.

show abstract

“…Various approaches have been reported in literature in order to reduce these severe systemic toxicities and enhance antitumor effects of CPT. These includes conjugation to synthetic polymers [28][29][30][31], incorporation into liposomes [32,33], microspheres [34,35], nanohybrids [36], and polymeric micelles [37][38][39][40][41].…”

Section: Introductionmentioning

confidence: 99%

Mixed PEG–PE/vitamin E tumor-targeted immunomicelles as carriers for poorly soluble anti-cancer drugs: Improved drug solubilization and enhanced in vitro cytotoxicity

Sawant

Torchilin

2008

European Journal of Pharmaceutics and Biopharmaceutics

View full text Add to dashboard Cite

Two poorly soluble, potent anticancer drugs, paclitaxel and camptothecin, were successfully solubilized by mixed micelles of polyethylene glycol-phosphatidyl ethanolamine (PEG-PE) and vitamin E. Drug containing micelles were additionally modified with anti-nucleosome monoclonal antibody 2C5 (mAb 2C5), which can specifically bring micelles to tumor cells in vitro. The optimized micelles had an average size of about 13-to-22 nm and the immuno-modification of micelles did not significantly change it. The solubilization of both drugs by the mixed micelles was more efficient than by micelles made of PEG-PE alone. Solubilization of camptothecin in micelles prevented also the hydrolysis of active lactone form of the drug to inactive carboxylate form. Drug loaded mixed micelles and mAb 2C5-immunomicelles demonstrated significantly higher in vitro cytotoxicity than free drug against various cancer cell lines.

show abstract

Molecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides

Cited by 161 publications

References 34 publications

Receptor targeted polymers, dendrimers, liposomes: Which nanocarrier is the most efficient for tumor-specific treatment and imaging?

Receptor targeted polymers, dendrimers, liposomes: Which nanocarrier is the most efficient for tumor-specific treatment and imaging?

TAT-LHRH conjugated low molecular weight chitosan as a gene carrier specific for hepatocellular carcinoma cells

Mixed PEG–PE/vitamin E tumor-targeted immunomicelles as carriers for poorly soluble anti-cancer drugs: Improved drug solubilization and enhanced in vitro cytotoxicity

Contact Info

Product

Resources

About